Pharmaceutics 16 , 849
However, another study with similar design did not see any association between GLP-1RA exposure and changes in new-onset depression or self-harm over 16,910 patients with diabetes over approximately 1 year of follow-up 201
Timing Follow-up Marker Lipid panel Why it matters Tracks cholesterol and triglyceride changes that may shift during weight-loss phases
Measure the dose
Funding This work was supported by the National Natural Science Foundation of China (31870906, 81974254, 82170470, and 82270903), Hubei Provincial Natural Science Foundation (2022CFB453), Foundation of Health Commission of Hubei (WJ2021M061, WJ2019F071), the Natural Science Foundation of the Bureau of Science and Technology of Shiyan City (grant no
-1 -1 [1] [2] glucagon-like peptide-1GLP-13031 [3] [4] proglucagonL [5] GLP-1 -1 -1 [6] [7] -1 [8] [9] GLP-1 [10] [11] GIPincretin GLP-1 [12] GIP2GLP-1 [13] 2000GLP-120054ByettaFDA20098 GLP-1(1-37) GLP-1(7-36)NH 2 GLP-1(7-37) [14] [15] [16] GLP-1 13-20 24-35 [17] GLP-1-4DPP-424.11NEP 24.112 [18] 10%15%GLP-1GLP-10-15 pmol/LGLP-1DPP-4GLP-1GLP-12 [19] [] L mRNA180 2PC2GRPP1IP-1MPGF PC1/3glicentinGRPPOxyntomodulinGLP-12IP-2-2GLP-2 GLP-172-108MPGFNGLP-178-107 GLP-11-37GLP-17-37 108CGLP-17-36 80%GLP-1GLP-17-37 [] GLP-1LLL GLP-110-1530-60LLLLGLP-1 GLP-1015 pmol/L23GLP-1 LCaGLP-1CaCaGLP-1 [] GLP-1-4DPP-4DPP-4Ala8Glu9GLP-1936GLP-160%80%DPP-4DPP-4GLP-125%GLP-1DPP-440%50%GLP-1DPP-410%15%GLP-1 24.11NEP 24.11GLP-1NGLP-150%DPP-4NEP 24.11GLP-1DPP-4GLP-1 GLP-12GLP-1 [] GLP-1GLP-1-4dipeptidyl peptidase-4DPP-4t1/2-4GLP-12GLP-12GLP-1 GLP-1GLP-1GLP-1GATPcAMPPKAEpac2CaATP GLP-1mRNAGLP-112GLP-1 GLP-1GLP-1GLP-1GLP-1GLP-1 GLP-1GLP-1GLP-1 GLP-1 [] 1902BaylissStarling1 [20] 1960 [21] 1982Richard GoodmanPP
